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Invited Commentary
Immunology of pre- and probiotic supplementation
(First published online 25 June 2008)
The notion that ingestion of so-called ‘good’ bacteria (‘probio-
tics’) or food components favouring growth of probiotic bac-
teria (‘prebiotics’) can have advantageous effects on human
health arouses strong opinions, both in agreement and against.
Remarkably few data have been fuelling this debate. Never-
theless, two important studies have now appeared, one pub-
lished in The Lancet showing that probiotic supplementation
in patients with acute pancreatitis is deleterious(1) and one in
this issue of the British Journal of Nutrition by Arribas
et al. (2), showing the beneficial effects of Lactobacillus fer-
mentum in an experimental model of septic shock. Together
with existing studies on the immunological effects of pre-
and probiotic food supplementation, the main effects of such
treatment seems localised to inducing anergy in the T cell
compartment. Health claims of pre- and probiotic treatment
should be interpreted within this framework.
The mucosal surface of the intestine represents the major
contact of the body with microbiological stimuli and in this
compartment is most of the immunological activity of the
body. Despite the bewildering number of bacteria in the intes-
tine, especially the colon, in most cases the human immune
system acts to tolerate harmless bacteria while eliminating
pathogenic bacteria. A variety of immunological mechanisms,
which include the existence of an efficient colonic columnic
epithelial barrier, the production of antibacterial peptides
(for example, the production of a-defensins by the Paneth
cells), constant sentinel-like surveillance by CD16low mono-
cytes and efficient recruitment of granulocytes to areas in
which barrier integrity has been compromised mediates pro-
tection of the body against the microbiological onslaught on
the mucosal surface(3). Counterintuitively, reduced activity
of these innate mechanisms, as a consequence of genetic
defects, seems responsible for chronic intestinal inflammation
in Crohn’s disease, which is associated with an abnormally
exaggerated mucosal immune response to an otherwise
normal intestinal flora(4). The sheer size of the mucosal
immune system as compared with other parts of the immune
system makes the notion that influencing the mucosal
immune system by dietary means plausible.
It usually assumed that the flora along the intestinal tract is
established early in life and in mammalian organisms resembles
the flora of the mother and is stable. Nevertheless, pre- or probio-
tic treatment seems capable of at least temporally altering this
composition. Probiotics are a group of bacteria of which theLac-
tobacilli and Bifidobacteria are the most prominent members
and it is claimed that they have anti-inflammatory properties.
Accordingly, such probiotic bacterial strains protect against
experimental colitis in rodents(5 – 7) as well as exacerbations of
inflammatory bowel disease(8) and topical allergy(9,10) in
human patients. In agreement, food supplements specifically
enhancing the growth of probiotic bacteria are recognised to
be beneficial in a variety of inflammatory conditions including
inflammatory bowel disease(11,12) and genetically engineering
plants for the production of prebiotics has become an industry
in its own right(13,14) despite limited insight into the immuno-
logical mechanisms induced by such food supplementation. In
contrast to most micro-organisms, some probiotic bacteria are
capable of impairing the immunological reaction to their muco-
sal presence in particular and have a dampening effect on the
adaptive immune system in general. To a certain extent probio-
tics exert their action by niche occupation and thus preventing
colonisation of the bowel by pathogenic bacterial species(15 – 17).
Moreover, it has become clear that probiotic bacteria directly
influence host physiology, especially barrier function(18,19),
but their anti-inflammatory effects in inflammatory bowel dis-
ease(20) and topical allergic disease(20,21) suggest that a direct
effect on the immune system is involved as well. As inflamma-
tory bowel disease displays mainly Th1 characteristics and
topical allergies are characterised by a Th2 phenotype and
both benefit from probiotic supplementation, the immunological
effects of probiotic bacteria probably do not involve altered Th1/
Th2 polarisation. There is evidence from a double-blind pla-
cebo-controlled study that Lactobacillus reuteri protectis
reduces short-term sick-leave from work caused by respiratory
or gastrointestinal infections(22 – 24). This effect is also not
easily explained via an influence on altered Th1/Th2 polaris-
ation but suggests effects of probiotic treatment at a more funda-
mental level of human immunobiology.
The study of Arribas et al. (2), which documents a preven-
tive effect of Lactobacillus fermentum in a murine model of
septic shock, provides important clues as to what these mecha-
nisms might be. The authors document markedly reduced sple-
nic T cell responses, suggesting that the T cell compartment
might be the relevant target for many of the effects observed
by probiotics. Also, the earlier observation reported by the
same laboratory that different probiotic bacteria, as well as
prebiotics, are beneficial in a trinitrobenzenesulfonic acid
model of rat colitis (which represents a classical T cell-
mediated inflammation) points in this direction. Interestingly,
both in vitro as well as in human volunteers or patients
with Crohn’s disease, Lactobacillus rhamnosus induced an
anergy-like T cell hyporesponsiveness which was apparently
mediated via reduced co-stimulatory activity in dendritic
cells(25), which fits well with a scheme that pre- and probiotics
act through diminished T cell activation(25). This hypothesis
also proves exceedingly useful in explaining the clinical
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efficacy in Crohn’s disease of Lactococcus lactis expressing
IL-10 where intravenous application of this IL is clinically
not useful(26,27); the bacterial context of the IL-10 might
result in combined T cell anergy and IL-10-dependent induc-
tion of tolerance and thus be synergistic. In this context it
should prove highly interesting to compare the efficacy of
Lactococcus lactis expressing IL-10 to the mother organism
not expressing IL-10 in Crohn’s disease, but such a study
has not been performed.
The molecular basis of the immunological modulation by pre-
and probiotics on T cell reactivity remains unaddressed, but may
lie in the secretion of soluble factors interfering with dendritic
cell specific intercellular adhesion molecule 3-grabbing noninte-
grin (DC-SIGN)(28). This may provide the bacterium with an
evasive strategy with respect to the immune system and hence
a competitive advantage at the mucosal surface and thus provide
the bacterium with a niche for cell growth in the bowel.
How bacteria prevent other micro-organisms from profiting
from this niche is unclear, but evidence exists, for instance,
that Lactobacillus rhamnosus is able to suppress the growth of
a diverse range of other bacteria via a variety of strategies(29–31).
Strikingly, in the recent trial of probiotics in human acute
pancreatitis(1) the supermortality in the probiotic-treated
group seemed mainly due to enhanced bowel ischaemia in
these patients. Since there is good evidence linking bowel
ischaemia severity to reduced T cell reactivity(27), effects of
probiotic bacteria on T cell reactivity may be linked to nega-
tive effects of probiotics in this disease.
In conclusion, also based on the study by Arribas et al. (2), a
picture emerges in which pre- and probiotics exert a class
effect on reactivity in the T cell compartment, possibly
mediated via reduced co-stimulatory activity of dendritic
cells. In view of this class effect, the current emphasis in
the field that each different pre- and probiotic should be con-
sidered individually and that results obtained with different
strains should not be extrapolated to related strains may be
somewhat overemphasised. In other words, the bioanalytical
profiling of both host microbiota and probiotic will be crucial
for defining how best to apply prebiotics and probiotics: opti-
mal dosage, frequency, duration, and consequently providing a
rational basis for supporting the belief that their consumption
results in health benefits.
The authors have no conflict of interest to declare.
Maikel P. Peppelenbosch
Department of Cell Biology
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